Adjunct Faculty
Adjunct faculty typically have an academic or research appointment at another institution and contribute or collaborate with one or more School of Medicine faculty members or programs.
Adjunct rank detailsThomas Prebet, MD, PhD
Associate Professor AdjunctDownloadHi-Res Photo
About
Copy Link
Titles
Associate Professor Adjunct
Biography
After completing his doctorate in medical hematology and oncology in Lyon, France, Dr. Prebet joined Institut Paoli-Calmettes in Marseille, France and completed a fellowship in Johns Hopkins University (Baltimore, MA, USA) as a Fullbright alumni. Dr. Prebet is currently the director of the inpatient hematology unit and the medical director of the hematology division of Yale Clinical Trial Office. He is the associate director of the myeloid malignancies program in the hematology department of the Yale Cancer Center, New haven, CT. He is developing myeloid malignancies clinical trials and translational works for advanced phase acute myeloid leukemia and myelodysplastics syndromes. The current works gave the basis for defining demethylating agent failure outcome (Prebet JCO 2011, Hematologica 2012, British Journal of Hematology 2012, Blood Advance 2018), contributed to his knowledge of combinations therapies based on HDAC inhibitors (Prebet JCO 2014, Prebet Leuk Res 2014) and gave the first insights on the implication of Wnt non canonical pathway in acute myeloid leukemia (Prebet Blood 2011). Dr Prebet is the coordinating investigator of several clinical trials for myelodysplastic syndromes and acute leukemia patients and contributed to 110 peer reviewed manuscript.
Last Updated on February 11, 2025.
Appointments
Medical Oncology and Hematology
Associate Professor AdjunctPrimary
Other Departments & Organizations
- Hematology
- Internal Medicine
- Medical Oncology and Hematology
- Yale Medicine
Education & Training
- Post-Doctoral Fellow
- Johns Hopkins University (2010)
- PhD
- Centre de Recherche en Cancerologie (2009)
- MS
- Claude Bernard University (2005)
- Resident
- University Hospitals of Lyon (2004)
- MD
- Montpellier University (2000)
Research
Copy Link
Overview
Medical Research Interests
Hematology; Leukemia; Myelodysplastic Syndromes
ORCID
0000-0002-6872-625X
Research at a Glance
Yale Co-Authors
Frequent collaborators of Thomas Prebet's published research.
Publications Timeline
A big-picture view of Thomas Prebet's research output by year.
Research Interests
Research topics Thomas Prebet is interested in exploring.
Amer Zeidan, MBBS
Jan Philipp Bewersdorf, MD, FACP
22Publications
900Citations
Myelodysplastic Syndromes
Publications
2025
Oral azacitidine maintenance therapy for patients with acute myeloid leukaemia and myelodysplasia‐related changes: Post hoc analysis of the QUAZAR AML‐001 trial
Voso M, de Botton S, Pfeilstöcker M, Alvarez A, Wang K, See W, Guerrero M, de Menezes D, Petrlik E, Prebet T, Roboz G. Oral azacitidine maintenance therapy for patients with acute myeloid leukaemia and myelodysplasia‐related changes: Post hoc analysis of the QUAZAR AML‐001 trial. British Journal Of Haematology 2025 PMID: 41387169, DOI: 10.1111/bjh.70272.Peer-Reviewed Original ResearchTime-dependent long short-term memory neural cox regression in 2,690 patients with myeloid neoplasias treated with diverse therapies identifies bone marrow related information to be less important than expected in the context of other available clinical parameters: Insights from the AML-001 trial (NCT01074047) and the austrian myeloid registry (NCT04438889) of the AGMT study group
Pleyer L, Zhang X, Drost M, Oberlechner J, Angermann H, Pfeilstöcker M, Petzer V, Heibl S, Moritz J, Girschikofsky M, Stampfl-Mattersberger M, Pichler A, Hartmann B, Aschauer G, Schmitt C, Vallet S, Boros S, Pichler P, Hammerl-Steiner A, Andel J, de Menezes D, Prebet T, Zeidan A, Zaborsky N, Greil R, Melchardt T, Gaugler L, Hasenauer J, Vaisband M. Time-dependent long short-term memory neural cox regression in 2,690 patients with myeloid neoplasias treated with diverse therapies identifies bone marrow related information to be less important than expected in the context of other available clinical parameters: Insights from the AML-001 trial (NCT01074047) and the austrian myeloid registry (NCT04438889) of the AGMT study group. Blood 2025, 146: 48. DOI: 10.1182/blood-2025-48.Peer-Reviewed Original ResearchConceptsBone marrow evaluationPeripheral blood dataCox proportional hazardsComplete remissionFollow-upComposite CRMyeloid neoplasiaMorphologic complete remissionLong short-term memoryRCT dataReal-world evidenceBlood count parametersSurvival predictionBlood dataDifferential blood countTime-to-eventTime-dependent concordance indexOverall survival predictionPrognostic equivalenceMarrow evaluationMedian FUTherapy cyclesClinical parametersNon-invasive alternativeTreatment startBMS-986397, a first-in-class casein kinase 1α (CK1α) degrader in patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR-MDS): A phase 1 dose escalation study
DiNardo C, Rodríguez-Arbolí E, Esteve J, Salamero O, Brunner A, Calbacho M, Deangelo D, Purroy N, Limones J, Jimenez C, Hu H, McTume G, Jimenez M, Estrada J, Qian Y, Carrancio S, Prebet T, Campbell T, Pourdehnad M, Uy G. BMS-986397, a first-in-class casein kinase 1α (CK1α) degrader in patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR-MDS): A phase 1 dose escalation study. Blood 2025, 146: 1642. DOI: 10.1182/blood-2025-1642.Peer-Reviewed Original ResearchConceptsTreatment-emergent AEDose-limiting toxicityMaximum tolerated doseDose-dependent increaseOpen-label studyHR-MDSDose interruptionR/R AMLSecondary AMLHR-MDS patientsAML patientsPeripheral bloodBone marrowClinical dataPhase 1 dose-escalation studyHigh-risk myelodysplastic syndromeAbsence of active diseaseDay 5Grade 4 cytopeniasLoss of 17pMedian prior linesMIC-1 levelsR/R AML patientsHigh-risk MDSMedian treatment durationMeasurable residual disease (MRD) as a surrogate end point for clinical drug approval in acute myeloid leukemia (AML): Perspectives from the MRD Partnership and Alliance in AML Clinical Treatment Consortium
Boyiadzis M, Wei A, Paiva B, Freeman S, Kaspers G, Chyla B, Hersey S, Patel R, Maloney B, Zumofen M, Van Hoef M, Wulff B, Obourn V, Patel S, de Menezes D, Shi Q, Bengoudifa B, Dimier N, Prior T, Roboz G, Prebet T. Measurable residual disease (MRD) as a surrogate end point for clinical drug approval in acute myeloid leukemia (AML): Perspectives from the MRD Partnership and Alliance in AML Clinical Treatment Consortium. Cancer 2025, 131: e35960. PMID: 40576165, PMCID: PMC12203635, DOI: 10.1002/cncr.35960.Peer-Reviewed Original ResearchAltmetricMeSH Keywords and ConceptsConceptsMeasurable residual diseaseAcute myeloid leukemiaSurrogate end pointsEnd pointsClinical trialsResidual diseaseMyeloid leukemiaClinical trial end pointsAcute myeloid leukemia therapyTrial end pointsAssessment of disease burdenAcute myeloid leukemia clinical trialsUnmet medical needMRD assessmentOverall survivalImproved survivalPatient subgroupsTherapeutic decisionsPatient groupPatientsPatient outcomesClinical treatmentAssessment timepointsDisease burdenDrug approvalReal‐world treatment patterns and outcomes with oral azacitidine maintenance therapy in patients with acute myeloid leukemia
Leber B, Ruiz M, Elgendy H, Pettersson F, Prebet T, Vigil C, Parikh R, Korgaonkar S, Bello F, Davis K, Gaugler L, Strocchia M, Sieluk J, Li Y, Schuh A. Real‐world treatment patterns and outcomes with oral azacitidine maintenance therapy in patients with acute myeloid leukemia. Cancer 2025, 131: e35845. PMID: 40233158, DOI: 10.1002/cncr.35845.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsAcute myeloid leukemiaRelapse-free survivalOral-AZAMaintenance therapyMyeloid leukemiaClinical characteristicsTreatment patternsFollow-upSafety outcomes of patientsHematopoietic stem cell transplantationReal-world treatment patternsMedian Follow-UpStem cell transplantationEuropean LeukemiaNet classificationKaplan-Meier methodologyOverall survival outcomesOutcomes of patientsMedical record reviewInclusion of patientsOral azacitidineConsolidation therapyInduction therapyInduction regimensOverall survivalCell transplantation
2024
Oral azacitidine maintenance after intensive chemotherapy versus venetoclax and azacitidine: real world outcomes in newly diagnosed acute myeloid leukemia
Mims A, Xie Z, Potluri R, Rotter D, Chevli M, Prebet T, Gaugler L, Strocchia M, Vasconcelos A, Sieluk J. Oral azacitidine maintenance after intensive chemotherapy versus venetoclax and azacitidine: real world outcomes in newly diagnosed acute myeloid leukemia. Leukemia & Lymphoma 2024, 66: 479-487. PMID: 39606887, DOI: 10.1080/10428194.2024.2425792.Peer-Reviewed Original ResearchConceptsRelapse-free survivalNewly diagnosed acute myeloid leukemiaOral-AZAIntensive chemotherapyAcute myeloid leukemiaOverall survivalMyeloid leukemiaMedian relapse-free survivalFlatiron Health databasePropensity score matched cohortCompare treatment patternsScore-matched cohortAzacitidine maintenanceND-AMLOral azacitidineMedian OSRetrospective studyClinical outcomesTreatment patternsAzacitidineTransplant candidatesPatientsReal-world outcomesRemissionChemotherapyAML-MR Mutations Drive the Benefit of CPX-351 over 7+3 in the Pivotal Phase 3 AML Trial
Shimony S, Murdock H, Keating J, Reilly C, Tsai H, Gibson C, Faderl S, Wagner T, Dronamraju N, Lin T, Ritchie E, Prebet T, Cortes J, Uy G, Lancet J, Neuberg D, Stone R, Lindsley R. AML-MR Mutations Drive the Benefit of CPX-351 over 7+3 in the Pivotal Phase 3 AML Trial. Blood 2024, 144: 60-60. DOI: 10.1182/blood-2024-200413.Peer-Reviewed Original ResearchCitationsConceptsAcute myeloid leukemiaTherapy-related AMLGermline DDX41 mutationsCPX-351Platelet recovery timeTP53 mutationsOverall survivalDDX41 mutationsTreatment armsCR/CRi rateMedian OSS-AMLPrognosis of t-AMLTherapy-related acute myeloid leukemiaAnalyzed outcomesSecondary acute myeloid leukemiaAML classificationSubsets of acute myeloid leukemiaConcurrent TP53 mutationImproved overall survivalHistory of MDSDe novoPhase 3 trialFavorable treatment outcomesTargeted mutation analysisLenalidomide in Transfusion-Dependent IPSS Low- or Intermediate-1-Risk Myelodysplastic Syndromes and Isolated Del(5q): Results of a European Postauthorization Safety Surveillance Study
Poloni A, Raaschou-Jensen K, Mohedo F, Paolini S, Oliva E, Buccisano F, Vasconcelos A, Kim I, Makwana A, Bernasconi D, Rosettani B, Prebet T, Santini V. Lenalidomide in Transfusion-Dependent IPSS Low- or Intermediate-1-Risk Myelodysplastic Syndromes and Isolated Del(5q): Results of a European Postauthorization Safety Surveillance Study. Clinical Lymphoma Myeloma & Leukemia 2024, 25: e131-e142. PMID: 39516085, DOI: 10.1016/j.clml.2024.10.007.Peer-Reviewed Original ResearchCitationsAltmetricConceptsInternational Prognostic Scoring SystemDose of lenalidomideMyelodysplastic syndromeIsolated del(5qAcute myeloid leukemiaBenefit-risk profileSafety populationTransfusion-DependentOverall survivalCumulative incidenceCumulative incidence of acute myeloid leukemiaGrade 3/4 treatment-emergent adverse eventsNon-interventional post-authorization safety studyInternational Prognostic Scoring System low-Intermediate-1-risk myelodysplastic syndromeIncidence of acute myeloid leukemiaLower-risk myelodysplastic syndromesTreatment-emergent adverse eventsEffects of lenalidomidePrognostic scoring systemKaplan-Meier analysisPost-authorization safety studyRoutine careClinical trial dataSafety surveillance studyHealthcare Utilization and Costs Among Patients with Acute Myeloid Leukemia Receiving Oral Azacitidine Maintenance Therapy Versus No Maintenance: A US Claims Database Study
Borate U, Seiter K, Potluri R, Mazumder D, Chevli M, Prebet T, Gaugler L, Strocchia M, Vasconcelos A, Sieluk J. Healthcare Utilization and Costs Among Patients with Acute Myeloid Leukemia Receiving Oral Azacitidine Maintenance Therapy Versus No Maintenance: A US Claims Database Study. Advances In Therapy 2024, 41: 4049-4064. PMID: 39240504, PMCID: PMC11480148, DOI: 10.1007/s12325-024-02947-1.Peer-Reviewed Original ResearchAltmetricConceptsAcute myeloid leukemiaHealthcare resource utilizationOral-AZAPropensity score matchingMyeloid leukemiaReal-world healthcare resource utilizationClinical practiceHematopoietic stem cell transplantationLower healthcare resource utilizationResultsAfter propensity score matchingStem cell transplantationContinuous insurance enrollmentClaims database studyOutpatient visitsOral azacitidinePost-remissionMaintenance therapyProlonged remissionCell transplantationDisease remissionDelayed relapseBaseline characteristicsTreatment patternsPatientsDatabase studyLuspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): primary analysis of a phase 3, open-label, randomised, controlled trial
Della Porta M, Garcia-Manero G, Santini V, Zeidan A, Komrokji R, Shortt J, Valcárcel D, Jonasova A, Dimicoli-Salazar S, Tiong I, Lin C, Li J, Zhang J, Pilot R, Kreitz S, Pozharskaya V, Keeperman K, Rose S, Prebet T, Lai Y, Degulys A, Paolini S, Cluzeau T, Fenaux P, Platzbecker U. Luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): primary analysis of a phase 3, open-label, randomised, controlled trial. The Lancet Haematology 2024, 11: e646-e658. PMID: 39038479, DOI: 10.1016/s2352-3026(24)00203-5.Peer-Reviewed Original ResearchCitationsAltmetricConceptsLower-risk myelodysplastic syndromesRed blood cell transfusion independenceTreatment-emergent adverse eventsMedian Follow-UpEpoetin alfa groupMyelodysplastic syndromeLuspatercept groupTransfusion-DependentSerum erythropoietin concentrationPrimary endpointEpoetin alfaTransfusion independenceOpen-labelAlfa groupAdverse eventsFollow-upRed blood cell transfusion burdenErythropoietin concentrationIntention-to-treat populationControlled TrialsCommon grade 3Epoetin alfa recipientsMean haemoglobin increasePrimary analysisProportion of patients
Academic Achievements & Community Involvement
Copy Link
Activities
activity National Cancer Center Network
10/01/2017 - PresentCommitteesCommittee MemberDetailsAML committeeactivity Yale Human Research Protection Program
12/31/2016 - PresentCommitteesCommittee MemberDetailsHuman Investigation Committeeactivity Via Pathway Oncology
2018 - PresentPeer Review Groups and Grant Study SectionsCo-Chairactivity National Comprehensive Cancer Network
2018 - PresentPeer Review Groups and Grant Study SectionsCommittee Memberactivity Onco Hematology for Fullbright commission (French American scholar exchange commission)
2011 - PresentPeer Review Groups and Grant Study SectionsMember
Honors
honor Award from association Laurette Fugain
07/01/2012International AwardSociété Française d’hématologieDetailsFrancehonor Award from French transfusion medicine society
07/01/2011International Awardassociation recherche transfusion/ société Française de Transfusion SanguineDetailsFrance